Deciphering RAGE pathway in ARDS

Our research focuses on the implications of the receptor for advanced glycation end-products (RAGE) in acute lung injury and its resolution.

 

Our goals are to propose novel diagnostic and therapeutic strategies through a translational approach combining animal models, cell cultures and clinical studies.

Roles of RAGE axis in acute lung injury and its resolution

Acute respiratory distress syndrome (ARDS) is a major cause of respiratory failure and death and is characterized by lung epithelial and endothelial injury. Alveolar fluid transport function is critical for its resolution, but therapeutic approaches are limited. A better understanding of the pathophysiology of ARDS is mandatory in order to improve its prevention, detection and treatment.

We propose to characterize functional and biological determinants associated with the inhibition of the receptor for advanced glycation end-products (RAGE), a marker of alveolar type I cell injury. Our innovative project is multidisciplinary and aims at providing novel diagnostic and therapeutic tools.

Multipath approach to RAGE axis

Our goal is to decipher RAGE pathway during acute lung injury, through a translational approach including animal (mouse and pig models), cellular and clinical studies.  We will combine our competences in biochemistry, cellular biology, in vivo studies and clinical research to fully characterize sRAGE as a novel biomarker of lung epithelial injury during ARDS and to explore pathophysiologic and therapeutic implications of a multimodal approach to RAGE modulation in ARDS.